Capricor Therapeutics, Inc.

CAPR

$140M

Micro Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO160 employees

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 6, 2026

25w

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

1 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date CAP-1002 (standard)

8/6/2026

For duchenne muscular dystrophy. BLA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

CAP-1002

Cardiosphere-Derived Cells

Phase 3

Duchenne Muscular Dystrophy

OrphanFast Track

Deramiocel (CAP-1002)

Phase 3

Duchenne Muscular Dystrophy

CAP-2003

Phase 2

COVID-19 Cardiac

Cenderitide

Phase 2

Heart Failure

Allogeneic Cardiosphere-Derived Cells (CAP-1002)

Phase 2

Duchenne Muscular Dystrophy

Drug Name	Phase	Indication	Designations
CAP-1002 Cardiosphere-Derived Cells	Phase 3	Duchenne Muscular Dystrophy	OrphanFast Track
Deramiocel (CAP-1002)	Phase 3	Duchenne Muscular Dystrophy	-
CAP-2003	Phase 2	COVID-19 Cardiac	-
Cenderitide	Phase 2	Heart Failure	-
Allogeneic Cardiosphere-Derived Cells (CAP-1002)	Phase 2	Duchenne Muscular Dystrophy	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

CAPR News